"Neuroblastoma" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A common neoplasm of early childhood arising from neural crest cells in the sympathetic nervous system, and characterized by diverse clinical behavior, ranging from spontaneous remission to rapid metastatic progression and death. This tumor is the most common intraabdominal malignancy of childhood, but it may also arise from thorax, neck, or rarely occur in the central nervous system. Histologic features include uniform round cells with hyperchromatic nuclei arranged in nests and separated by fibrovascular septa. Neuroblastomas may be associated with the opsoclonus-myoclonus syndrome. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2099-2101; Curr Opin Oncol 1998 Jan;10(1):43-51)
| Descriptor ID |
D009447
|
| MeSH Number(s) |
C04.557.465.625.600.590.650.550 C04.557.470.670.590.650.550 C04.557.580.625.600.590.650.550
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Neuroblastoma".
- Diseases [C]
- Neoplasms [C04]
- Neoplasms by Histologic Type [C04.557]
- Neoplasms, Germ Cell and Embryonal [C04.557.465]
- Neuroectodermal Tumors [C04.557.465.625]
- Neoplasms, Neuroepithelial [C04.557.465.625.600]
- Neuroectodermal Tumors, Primitive [C04.557.465.625.600.590]
- Neuroectodermal Tumors, Primitive, Peripheral [C04.557.465.625.600.590.650]
- Neuroblastoma [C04.557.465.625.600.590.650.550]
- Neoplasms, Glandular and Epithelial [C04.557.470]
- Neoplasms, Neuroepithelial [C04.557.470.670]
- Neuroectodermal Tumors, Primitive [C04.557.470.670.590]
- Neuroectodermal Tumors, Primitive, Peripheral [C04.557.470.670.590.650]
- Neuroblastoma [C04.557.470.670.590.650.550]
- Neoplasms, Nerve Tissue [C04.557.580]
- Neuroectodermal Tumors [C04.557.580.625]
- Neoplasms, Neuroepithelial [C04.557.580.625.600]
- Neuroectodermal Tumors, Primitive [C04.557.580.625.600.590]
- Neuroectodermal Tumors, Primitive, Peripheral [C04.557.580.625.600.590.650]
- Neuroblastoma [C04.557.580.625.600.590.650.550]
Below are MeSH descriptors whose meaning is more specific than "Neuroblastoma".
This graph shows the total number of publications written about "Neuroblastoma" by people in this website by year, and whether "Neuroblastoma" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1991 | 0 | 1 | 1 |
| 1993 | 0 | 1 | 1 |
| 1994 | 1 | 0 | 1 |
| 1995 | 1 | 0 | 1 |
| 1996 | 0 | 2 | 2 |
| 1997 | 0 | 1 | 1 |
| 2000 | 1 | 0 | 1 |
| 2001 | 0 | 1 | 1 |
| 2002 | 0 | 2 | 2 |
| 2003 | 0 | 1 | 1 |
| 2004 | 0 | 1 | 1 |
| 2006 | 0 | 1 | 1 |
| 2007 | 2 | 0 | 2 |
| 2008 | 1 | 0 | 1 |
| 2009 | 2 | 0 | 2 |
| 2010 | 1 | 0 | 1 |
| 2011 | 3 | 0 | 3 |
| 2013 | 2 | 1 | 3 |
| 2014 | 1 | 2 | 3 |
| 2015 | 4 | 0 | 4 |
| 2016 | 1 | 0 | 1 |
| 2017 | 0 | 1 | 1 |
| 2019 | 2 | 0 | 2 |
| 2020 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Neuroblastoma" by people in Profiles.
-
Aravindan N, Herman T, Aravindan S. Emerging therapeutic targets for neuroblastoma. Expert Opin Ther Targets. 2020 09; 24(9):899-914.
-
Somasundaram DB, Subramanian K, Aravindan S, Yu Z, Natarajan M, Herman T, Aravindan N. De novo regulation of RD3 synthesis in residual neuroblastoma cells after intensive multi-modal clinical therapy harmonizes disease evolution. Sci Rep. 2019 08 13; 9(1):11766.
-
Somasundaram DB, Aravindan S, Yu Z, Jayaraman M, Tran NTB, Li S, Herman TS, Aravindan N. Droplet digital PCR as an alternative to FISH for MYCN amplification detection in human neuroblastoma FFPE samples. BMC Cancer. 2019 Jan 28; 19(1):106.
-
Aravindan S, Somasundaram DB, Kam KL, Subramanian K, Yu Z, Herman TS, Fung KM, Aravindan N. Retinal Degeneration Protein 3 (RD3) in normal human tissues: Novel insights. Sci Rep. 2017 10 13; 7(1):13154.
-
Ramraj SK, Aravindan S, Somasundaram DB, Herman TS, Natarajan M, Aravindan N. Serum-circulating miRNAs predict neuroblastoma progression in mouse model of high-risk metastatic disease. Oncotarget. 2016 Apr 05; 7(14):18605-19.
-
Khan FH, Pandian V, Ramraj SK, Aravindan S, Natarajan M, Azadi S, Herman TS, Aravindan N. RD3 loss dictates high-risk aggressive neuroblastoma and poor clinical outcomes. Oncotarget. 2015 Nov 03; 6(34):36522-34.
-
Khan FH, Pandian V, Ramraj S, Natarajan M, Aravindan S, Herman TS, Aravindan N. Acquired genetic alterations in tumor cells dictate the development of high-risk neuroblastoma and clinical outcomes. BMC Cancer. 2015 Jul 10; 15:514.
-
Khan FH, Pandian V, Ramraj S, Aravindan S, Herman TS, Aravindan N. Reorganization of metastamiRs in the evolution of metastatic aggressive neuroblastoma cells. BMC Genomics. 2015 Jul 07; 16:501.
-
Pandian V, Ramraj S, Khan FH, Azim T, Aravindan N. Metastatic neuroblastoma cancer stem cells exhibit flexible plasticity and adaptive stemness signaling. Stem Cell Res Ther. 2015 Feb 20; 6:2.
-
Czarnecka M, Trinh E, Lu C, Kuan-Celarier A, Galli S, Hong SH, Tilan JU, Talisman N, Izycka-Swieszewska E, Tsuei J, Yang C, Martin S, Horton M, Christian D, Everhart L, Maheswaran I, Kitlinska J. Neuropeptide Y receptor Y5 as an inducible pro-survival factor in neuroblastoma: implications for tumor chemoresistance. Oncogene. 2015 Jun 11; 34(24):3131-43.